Eg5 expression in patients with non-small cell lung cancer (NSCLC) was correlated with cyclin B1 expression and appeared to be predictive of improved clinical response to antimitotic agents in combination with platinum therapy. Here, KIF11 is linked to non-small cell lung carcinoma.